Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Development

Efficacy Studies

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Regulatory decisions await further phase 3 data in 2026.

FDA Approves Two First-in-Class Oral Treatments for Gonorrhea